Scientist Quarrel Over Kite Pharma Sale Royalties to be Settled Out of Court

Israeli immunologist Zelig Eshhar, who holds the patent for Kite Pharma’s anti-cancer technology, has been sued by a former student for infringement of patent rights

Israeli Immunologist Zelig Eshhar, who holds the patent to the technology used to develop Kite Pharma’s anti-cancer treatment, and Gideon Gross, the former Ph.D. student who is currently suing him for infringement of patent rights, have agreed to attempt arbitration, according to a document filed with an Israeli district court last week. The two have yet to choose an arbitrator.

 

For daily updates, subscribe to our newsletter by clicking here.

 

In August 2017, Gilead Sciences Inc. acquired Kite Pharma for $11.9 billion, banking on the approval of its novel cancer treatment technology. Chimeric antigen receptor T-cell therapy, or CAR-T, is a technology that engineers a patient’s own immune cells to better fight their specific cancer. The technology was approved by the U.S. Food and Drug Administration in October, and Gilead set the price for a single treatment course at $373,000.

 

Zelig Eshhar at his office. Photo: The Weizmann Institute of Science

 

 

Mr. Eshhar, who is the chair of immunology research at the Tel Aviv Sourasky Medical Center and a pioneer of CAR-T research, sold the patent rights to Kite Pharma in 2013 and is also a member of the company’s scientific board. Following the sale, his options were valued at $72 million.

 

Mr. Gross discovered CAR-T technology in the 1980s as part of his Ph.D. research under Mr. Eshhar, and the original patent was filed under his name as well.

 

In September, Mr. Gross sued Mr. Eshhar in Israeli court, alleging that he agreed to award Mr. Eshhar all patent rights in return for property rights and a share of the intake, but Mr. Eshhar failed to deliver and furthermore, hid pertinent information from Mr. Gross. He asked for 15% of Mr. Eshhar's options. On September 26 the court issued a temporary injunction, preventing Mr. Eshhar from making changes to his options.

 

Related stories:

• Scientist’s Ex-Wife Joins Legal Melee Over Kite Pharma Windfall
• Immunologists Exchange Verbal Blows in Legal Fight Over Kite Pharma Windfall
• Kite Pharma Sale Triggers Scientist Quarrel

 

On his part, Mr. Eshhar said his options were received due to his work as a scientific advisor to Kite Pharma and were not related to the patent. He stated that Mr. Gross has already received $1.5 million in royalties, calling his allegations “baseless” and “ungrateful."

 

Last month, the presiding judge in the case made the suggestion of arbitration, stating that the nature of the case and the dispute make it better suited for a resolution outside of court.